CHAD Therapeutics receives FDA clearance for sleep diagnostic device

6 August 2008

Dormio Tech, a division of CHAD Therapeutics, Inc. (AMEX:CTU), has received 510(K) clearance from the FDA for its FloChannel Diagnostic System, Dormio's first product for the large and rapidly growing sleep disorder market.

"With its patented features and unique capabilities, we believe FloCHANNEL is a significant advance in the diagnosis of obstructive sleep apnea and other sleep disorders, and may become an invaluable tool in attended sleep laboratories," said President and CEO Earl Yager. There are approximately 2,800 attended sleep labs in the United States.

Dormio Tech says its FloChannel is the only diagnostic device that independently monitors left and right nasal airflow. This allows the system to detect and measure nasal cycling (the periodic alternation in nasal airflow resistance between the two nasal cavities), as well as oral airflow and snoring, and provides constant baseline airflow volumetric sleep scoring. The patented device connects easily to standard sleep lab systems.

CHAD currently expects to begin shipping the device and associated disposables by September this year.

To top